APTO vs. SRZN, EVAX, PMCB, AIM, IKT, SNTI, NKGN, COEP, SRNE, and GENE
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Surrozen (SRZN), Evaxion Biotech A/S (EVAX), PharmaCyte Biotech (PMCB), AIM ImmunoTech (AIM), Inhibikase Therapeutics (IKT), Senti Biosciences (SNTI), NKGen Biotech (NKGN), Coeptis Therapeutics (COEP), Sorrento Therapeutics (SRNE), and Genetic Technologies (GENE). These companies are all part of the "biological products, except diagnostic" industry.
Surrozen (NASDAQ:SRZN) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
Surrozen has higher revenue and earnings than Aptose Biosciences. Surrozen is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Aptose Biosciences' return on equity of -82.43% beat Surrozen's return on equity.
Aptose Biosciences received 372 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 65.91% of users gave Aptose Biosciences an outperform vote while only 16.67% of users gave Surrozen an outperform vote.
Aptose Biosciences has a consensus price target of $19.80, indicating a potential upside of 1,606.90%. Given Surrozen's higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Surrozen.
66.6% of Surrozen shares are owned by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are owned by institutional investors. 35.0% of Surrozen shares are owned by company insiders. Comparatively, 9.5% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Surrozen has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
In the previous week, Surrozen had 1 more articles in the media than Aptose Biosciences. MarketBeat recorded 2 mentions for Surrozen and 1 mentions for Aptose Biosciences. Surrozen's average media sentiment score of 1.00 beat Aptose Biosciences' score of 0.30 indicating that Aptose Biosciences is being referred to more favorably in the news media.
Summary
Aptose Biosciences beats Surrozen on 8 of the 15 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
